Shenzhen Hepalink Pharmaceutical Group Co Ltd

Common Name
Hepalink
Country
China (Mainland)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,926
Ticker
002399
Exchange
SHENZHEN STOCK EXCHANGE
Description
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a prominent pharmaceutical company specializing in the production and distribution of heparin and related products. Heparin, a critical anticoagulan...

Hepalink's GHG Emissions Data Preview

In 2024, Hepalink completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).

However, Hepalink has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)2024202320222021 - 2017
Total Scope 1
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
b
0000000
Total Scope 2
Unspecified Calculation Method
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
b
0000000
Total Scope 3
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
b
0000000
Download Data

Verified Sources Behind Hepalink’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Hepalink’s data sources below and access millions more through our Disclosure Search.

a. Hepalink's ESG Report 2024
a. Hepalink's ESG Report 2024
b. Hepalink's ESG Report 2023
b. Hepalink's ESG Report 2023

Insights into Hepalink's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions of Hepalink amounted to 51,613.7 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a

Compared to 2023, the total operational greenhouse gas (GHG) emissions of Hepalink decreased by 7.62%, showing that the company has made progress in taking action to reduce the climate impact of its operations. a

Hepalink's Scope 1 Emissions Over Time

20222023202406.5 k13 k19.5 k26 ktCO2e+1%-26%
  • Total Scope 1
  • Year-over-Year Change

What are Hepalink's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Hepalink were 18,284 metric tons of CO₂ equivalent (tCO₂e). a

Has Hepalink reduced its Scope 1 emissions over time?

Since 2022, Hepalink's Scope 1 emissions have decreased by 24.93%, reflecting a declining long-term trend in Scope 1 emissions over time. a b

Compared to the previous year (2023), Hepalink's Scope 1 emissions decreased by 25.89%, highlighting the company's efforts to lower direct emissions from assets it owns or controls. a

What are Hepalink's Scope 2 emissions?

In 2024, Hepalink reported Scope 2 greenhouse gas (GHG) emissions of 33,329.7 tCO₂e without specifying the calculation method. a

Has Hepalink reduced its Scope 2 emissions over time?

Since 2022, Hepalink's Scope 2 greenhouse gas (GHG) emissions ( Unspecified Calculation Method) have remained relatively stable, indicating that Hepalink 's emissions have plateaued with no significant change in its energy consumption footprint. a b

Compared to the previous year (2023), Hepalink's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Hepalink 's emissions have plateaued with no significant change in its energy consumption footprint. a

What methodology does Hepalink use for Scope 2 reporting?

In 2024, Hepalink reported its Scope 2 emissions using an unspecified methodology. a

Hepalink's Scope 2 Emissions Over Time

20222023202408.5 k17 k25.5 k34 ktCO2e
  • Total Scope 2 (Unspecified Calculation Method)

Insights into Hepalink’s GHG Emissions Intensity Compared to Industry Peers

In 2024, Hepalink reported Scope 1 greenhouse gas (GHG) emissions of 18,284 tCO₂e and total revenues of USD 724 millions. This translates into an emissions intensity of 25.27 tCO₂e per millions USD. a

Hepalink's Scope 1 Emissions Intensity Compared to Peers

102002,00050,000500,000Scope 1 Emissions (tCO2e)5502002,00010,000Revenues (Millions of USD)CCHHPDSDCCanSino BiologicsYear: 2023Scope 1: 3,541 tCO2eRevenue: $M 49Scope 1 Intensity: 72.91 tCO2e/$MSimcere Pharmaceutical GroupYear: 2023Scope 1: 4,997 tCO2eRevenue: $M 1,017Scope 1 Intensity: 4.91 tCO2e/$MWalvax BiotechnologyYear: 2024Scope 1: 7,643 tCO2eRevenue: $M 387Scope 1 Intensity: 19.77 tCO2e/$MCCCR Double-CraneYear: 2023Scope 1: 51,608 tCO2eRevenue: $M 1,438Scope 1 Intensity: 35.88 tCO2e/$MHumanwell Healthcare GroupYear: 2023Scope 1: 23,403 tCO2eRevenue: $M 3,451Scope 1 Intensity: 6.78 tCO2e/$MLuye Pharma GroupYear: 2023Scope 1: 10,755 tCO2eRevenue: $M 945Scope 1 Intensity: 11.38 tCO2e/$MLivzon Pharmaceutical GroupYear: 2024Scope 1: 194,441 tCO2eRevenue: $M 1,619Scope 1 Intensity: 120.13 tCO2e/$MCCChangchun High-TechYear: 2023Scope 1: 61,590 tCO2eRevenue: $M 2,050Scope 1 Intensity: 30.05 tCO2e/$MHansoh Pharmaceutical GroupYear: 2024Scope 1: 13,163 tCO2eRevenue: $M 1,830Scope 1 Intensity: 7.19 tCO2e/$MHHHygeia Healthcare HoldingsYear: 2023Scope 1: 2,681 tCO2eRevenue: $M 627Scope 1 Intensity: 4.27 tCO2e/$MHHHuadong MedicineYear: 2023Scope 1: 14,289 tCO2eRevenue: $M 5,716Scope 1 Intensity: 2.50 tCO2e/$MJoincareYear: 2024Scope 1: 197,854 tCO2eRevenue: $M 2,140Scope 1 Intensity: 92.45 tCO2e/$MPPPorton Pharma SolutionsYear: 2024Scope 1: 18,865 tCO2eRevenue: $M 413Scope 1 Intensity: 45.71 tCO2e/$MBioKangtaiYear: 2023Scope 1: 15,952 tCO2eRevenue: $M 489Scope 1 Intensity: 32.60 tCO2e/$MZhejiang Jiuzhou PharmaceuticalYear: 2023Scope 1: 48,815 tCO2eRevenue: $M 777Scope 1 Intensity: 62.81 tCO2e/$MYunnan Baiyao GroupYear: 2023Scope 1: 28,983 tCO2eRevenue: $M 5,503Scope 1 Intensity: 5.27 tCO2e/$MConsun Pharmaceutical GroupYear: 2023Scope 1: 54,210 tCO2eRevenue: $M 398Scope 1 Intensity: 136.27 tCO2e/$MDDDong-E-E-JiaoYear: 2023Scope 1: 15,659 tCO2eRevenue: $M 663Scope 1 Intensity: 23.60 tCO2e/$MFosun PharmaYear: 2024Scope 1: 184,016 tCO2eRevenue: $M 5,627Scope 1 Intensity: 32.70 tCO2e/$MSSSihuan PharmaceuticalYear: 2023Scope 1: 45,602 tCO2eRevenue: $M 286Scope 1 Intensity: 159.27 tCO2e/$MTasly Pharmaceutical GroupYear: 2024Scope 1: 37,370 tCO2eRevenue: $M 1,164Scope 1 Intensity: 32.09 tCO2e/$MHua MedicineYear: 2023Scope 1: 19 tCO2eRevenue: $M 12Scope 1 Intensity: 1.63 tCO2e/$MDDDa Ren TangYear: 2023Scope 1: 5,902 tCO2eRevenue: $M 1,157Scope 1 Intensity: 5.10 tCO2e/$MYuwellYear: 2023Scope 1: 2,201 tCO2eRevenue: $M 1,122Scope 1 Intensity: 1.96 tCO2e/$MCCChina Resources SanjiuYear: 2024Scope 1: 55,312 tCO2eRevenue: $M 3,784Scope 1 Intensity: 14.62 tCO2e/$MHepalinkYear: 2024Scope 1: 18,284 tCO2eRevenue: $M 724Scope 1 Intensity: 25.27 tCO2e/$M

How does Hepalink's GHG emissions intensity compare to its peers?

In 2024, Hepalink reported a Scope 1 emissions intensity of 25.27 tCO₂e per millions USD. Compared to the peer group median of 23.6 , this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors. a

Where does Hepalink rank on GHG emissions intensity within its industry?

In 2024, Hepalink ranked 14 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a

Hepalink is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency. a

Want Full Access to Hepalink's GHG Emissions Dataset?
Sign Up